There are vulnerabilities common to 3 deadly coronaviruses: SARS-CoV-2, SARS-CoV-1, and MERS-CoV, that could lead to promising targets for inactivating the Coronavirus, according to a global study.
The study was conducted by a research team that includes scientists from the Institute of Biomedical Sciences at Georgia State University, as its results, published in the journal Science, identify commonalities between coronaviruses while highlighting many common cellular processes, and protein targets that should be considered targets for therapeutic interventions for current and future epidemics.
The results were achieved through collaboration between nearly 200 researchers from more than 14 pioneering institutions in six countries. Dr. Christopher Päsler, professor and director of the Center for Microbial Pathogens at the Institute of Biomedical Sciences, led the effort in Georgia.
Previous studies have identified more than 300 host cell proteins that can interact with SARS-CoV-2 proteins. In this study, the Päsler laboratory examined the proteins for their ability to change how well the virus grows.
“The effort has identified at least 20 host genes, whose protein products dramatically alter the amount of virus that infected cells produce. These proteins represent potential targets for therapeutic intervention. For example, if a cellular protein is required for the effective growth of the virus, then the drug that is needed,” said Päsler. Inhibiting cellular protein should slow down the infection. ”
The multidisciplinary global study also analyzed the medical records of about 740,000 patients with SARS-CoV-2, to identify approved treatments with the potential for the rapid spread of the “Covid-19” treatment.